Seven of nine kids were desensitized to walnut and one other nut.
Therapy significantly increased the amount of wheat an allergic individual can tolerate without reacting.
Promising results from Viaskin patch research.
Peanut oral immunotherapy in a capsule is moving closer to regulatory approval in the United States. The therapy brings hope – not for a cure – but of lives made less vulnerable.
Why FARE (Food Allergy Research & Education) thinks desensitization is a vital food allergy therapy on the path toward finding tolerance.
A pharmaceutical approach to oral immunotherapy is a step closer to approval by the Food and Drug Administration. The treatment, called AR101, is being developed by a company called Aimmune Therapeutics. The company’s aim is to make people less allergic to peanuts by having them take a specially formulated peanut powder in increasing doses over… Read more »
While oral immunotherapy for peanut allergy grabs plenty of headlines, the question is often raised whether the technique will work for tree nuts as well. In a study presented at the AAAAI meeting in March 2016, researchers from the University of Arkansas say they’ve observed that walnut OIT can effectively and safely desensitize patients to… Read more »
In a long-term follow-up study, oral immunotherapy (OIT) patients who were treated for up to five food allergies were able to maintain a high level of desensitization to their allergens, even those taking very low “doses” of their allergens.
They’re the courageous food allergy parents and children testing therapies still in the experimental stages.
Patients taking the drug had one-third the number of reactions of a placebo group while doing OIT